Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B.
暂无分享,去创建一个
J. Connors | J. Spinelli | P. Hoskins | P. Klimo | V. Ng | J. M. Connors | Paul Hoskins | Vincent T. Y. Ng | John J. Spinelli
[1] J. Connors,et al. Updated clinical experience with MACOP-B. , 1987, Seminars in hematology.
[2] G. Pinkus,et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. , 1986, Annals of internal medicine.
[3] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[4] M. Pasmantier,et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.
[5] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[6] D. Rosenthal,et al. Combination chemotherapy of advanced non-Hodgkin lymphoma with bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP). , 1977, Blood.
[7] J. Hanley,et al. The effect of measuring error on the results of therapeutic trials in advanced cancer , 1976, Cancer.